Boosting Osimertinib Blood Brain Barrier Penetration

The goal of this proof-of-concept clinical study is to determine the effect of combining osimertinib with febuxostat on cerebrospinal fluid concentrations of osimertinib in patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). The main question it aims to answer is: what is the effect of combining osimertinib with the ABCG2 inhibitor febuxostat on cerebrospinal fluid to unbound plasma osimertinib concentration ratio in patients with EGFR mutated NSCLC without central nervous system (CNS) metastases and without the ABCG2 34G\>A single nucleotide polym

Trial Details

NCT ID
NCT07485452
Phase
PHASE2
Sponsor
Maastricht University Medical Center
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Osimertinib & febuxostat
Locations (sample)
  • Amsterdam, Netherlands|52.37403,4.88969
  • Maastricht, Netherlands|50.84833,5.68889

Key Eligibility Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • The patient has metastatic EGFR-mutated NSCLC and is treated with osimertinib as part of regular care with CT-confirmed stable disease or better. P…
  • The patient has an European Cooperative Oncology Group (ECOG) performance status (PS) of 0-2.
  • The patient is 18 years of age or older.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →